Status:

COMPLETED

Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborating Sponsors:

Brigham and Women's Hospital

Massachusetts General Hospital

Conditions:

Adenocarcinoma of Stomach

Adenocarcinoma of GE Junction

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to collect information on the anti-tumor activity of the combination doxorubicin, cisplatin, and 5-fluorouracil when given to patients with advanced esophageal or gastric ...

Detailed Description

* Patients will receive cisplatin and doxorubicin intravenously once every 3 weeks. In addition to cisplatin and doxorubicin, patients will receive 5-fluorouracil intravenously as a continuous infusio...

Eligibility Criteria

Inclusion

  • Measurable, locally unresectable or metastatic adenocarcinoma of the stomach, GE junction or esophagus
  • No more than one prior chemotherapy regimen
  • ECOG performance status of \< or equal to 2
  • Life expectancy \> 12 weeks
  • ANC \> 1,500/mm3
  • Hemoglobin \> 9.0 gm/dl
  • Platelets \> 100,000/mm3
  • SGOT \< 3 x ULN
  • Total bilirubin \< 2.0 mg/dl
  • Creatinine \< 1.5 mg/dl

Exclusion

  • Prior cisplatin or doxorubicin as neoadjuvant or adjuvant therapy with in 1 year of study entry
  • Clinically apparent central nervous system metastases or carcinomatous meningitis
  • Myocardial infarction in the past 6 months
  • Major surgery in the past 2 weeks
  • Uncontrolled serious medical or psychiatric illness
  • Pregnant or lactating women
  • Concurrent malignancy of any site, except limited basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
  • History or clinical evidence of congestive heart failure

Key Trial Info

Start Date :

August 1 1998

Trial Type :

INTERVENTIONAL

End Date :

January 1 2006

Estimated Enrollment :

32 Patients enrolled

Trial Details

Trial ID

NCT00165191

Start Date

August 1 1998

End Date

January 1 2006

Last Update

April 28 2009

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02115

2

Massachusetts General Hospital

Boston, Massachusetts, United States, 02115

Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus | DecenTrialz